Early-Stage Breast Cancer

Publication Date: December 12, 2016

Key Points

Key Points

Clinicians should NOT recommend axillary lymph node dissection (ALND) for women with early-stage breast cancer:

Who do not have nodal metastases. (EB, B, S, H)
3336
Who have one or two sentinel lymph node metastases and will receive breast-conserving surgery (BCSa.) with conventionally fractionated whole-breast radiotherapy (EB, B, S, H)
3336
Clinicians may offer ALND for women with early-stage breast cancer with nodal metastases found on sentinel lymph node (SNB) who will receive mastectomy. (EB, B, W, L)
3336

Clinicians may offer SNB for women who have operable breast cancer who have the following circumstances:

Multicentric tumors. (EB, B, M, I)
3336
Ductal carcinoma in situ (DCIS) when mastectomy is performed. (IC, B, W, Ins)
3336
Prior breast and/or axillary surgery. (EB, B, S, I)
3336
Preoperative/neoadjuvant systemic therapyb. (EB, B, M, I)
3336

There are insufficient data to change the 2005 recommendation that clinicians should NOT perform SNB for women who have early-stage breast cancer and are in the following circumstances:

Large or locally advanced invasive breast cancers (tumor size T3/T4). (IC, U, W, Ins)
3336
Inflammatory breast cancer. (IC, U, W, Ins)
3336
DCIS when breast-conserving surgery is planned. (IC, U, S, Ins)
3336
Pregnancy (IC, U, W, Ins)
a Clinicians should consider this recommendation with caution in patients with clinically enlarged axillary lymph nodes, those with large primary tumors (>5 cm), those with large or bulky metastatic axillary sentinel lymph nodes, and/or those with gross extranodal extension of the tumor.
b SNB may be offered before or after neoadjuvant chemotherapy (NACT), but the false negative rate is higher afterward, and therefore, the procedure seems less accurate after NACT and may be unacceptably high with known metastatic nodes.
3336

Illustration of Sentinel Nodes

...llustration of Sentinel...

...Sentinel Lymph Nodes...